Table 3 Presurgical imaging modalities and association with level of axillary nodal burden on pathology
No residual macrometastatic nodes n (%) | 1–2 residual metastatic nodes n (%) | More than 2 residual metastatic nodes n (%) | p-value | |
|---|---|---|---|---|
Total | 33 (38%) | 28 (32%) | 26 (30%) | |
MRI breast tumour phenotype: | ||||
Mass | 21 (41%) | 20 (39%) | 10 (20%) | |
Non-mass enhancement | 4 (33%) | 4 (33%) | 4 (33%) | 0.091 |
Both | 8 (33%) | 4 (17%) | 12 (50%) | |
MRI breast interim chemo: | ||||
Complete response | 10 (90%) | 0 | 1 (10%) | |
Partial response | 18 (40%) | 18 (40%) | 9 (20%) | < 0.0001 |
Stable disease | 3 (11%) | 9 (33%) | 15 (56%) | |
Progressive disease | 0 (0%) | 0 (0%) | 0 (0%) | |
MRI breast post chemo: | ||||
Complete response | 25 (64%) | 9 (23%) | 5 (13%) | < 0.0001 |
Partial response | 6 (15%) | 16 (40%) | 18 (45%) | |
Stable disease | 2 (40%) | 2 (40%) | 1 (20%) | |
Progressive disease | 0 (0%) | 1 (100%) | 0 (0%) | |
MRI axilla post chemo: | ||||
Normal | 21 (46%) | 13 (28%) | 12 (26%) | 0.087 |
Borderline | 7 (39%) | 7 (39%) | 4 (22%) | |
Abnormal (partial response) | 5 (31%) | 3 (19%) | 8 (50%) | |
Abnormal | 0 (0%) | 5 (71%) | 2 (29%) | |